Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. https://doi.org/10.3389/fonc.2018.00163. (Published 2018 Jun 4).
2. Major A, Smith SM. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? Clin Adv Hematol Oncol. 2021;19(11):698–709.
3. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer. 2005;103(8):1644–51. https://doi.org/10.1002/cncr.20956.
4. Lyman GH, Balaban E, Diaz M, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36(12):1260–5. https://doi.org/10.1200/JCO.2017.77.4893.
5. Biosimilar Product Information. U.S. Food and Drug Administration. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed Aug 7, 2022.